Abstract
In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 550-551 |
| Number of pages | 2 |
| Journal | Cancer Cell |
| Volume | 32 |
| Issue number | 5 |
| DOIs | |
| State | Published - Nov 13 2017 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cell Biology
- Cancer Research
Cite this
}
Molecular Landscape of Non-Muscle Invasive Bladder Cancer. / Meeks, Joshua J; Lerner, Seth P.
In: Cancer Cell, Vol. 32, No. 5, 13.11.2017, p. 550-551.Research output: Contribution to journal › Short survey
TY - JOUR
T1 - Molecular Landscape of Non-Muscle Invasive Bladder Cancer
AU - Meeks, Joshua J
AU - Lerner, Seth P.
PY - 2017/11/13
Y1 - 2017/11/13
N2 - In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.
AB - In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling. Tumors from female patients have a higher frequency of KDM6A mutations. In this issue of Cancer Cell, Hurst et al. report an integrated analysis of non-invasive (stage Ta) bladder cancer. Two genomic subtypes are distinguished by chromosome 9q loss, resulting in increased AKT/PI3K/mTOR signaling and increased risk of recurrence. Tumors from female patients have a higher frequency of KDM6A mutations.
UR - http://www.scopus.com/inward/record.url?scp=85033667156&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85033667156&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2017.08.015
DO - 10.1016/j.ccell.2017.08.015
M3 - Short survey
C2 - 29136502
AN - SCOPUS:85033667156
VL - 32
SP - 550
EP - 551
JO - Cancer Cell
JF - Cancer Cell
SN - 1535-6108
IS - 5
ER -